We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MF

News List

UK NICE recommends Kyowa Kirin’s Poteligeo for rare blood cancers Pharmaceutical-Technology
November 12, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Kyowa Kirin’s humanised monoclonal antibody, Poteligeo (mogamulizumab), to treat adult patients...
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) prnasia
July 06, 2021
Antengene recently announced that China's National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for single agent selinexor.
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients firstwordpharma
June 11, 2021
Kyowa Kirin today announced a new analysis of data showing statistically significant improvements in quality of life in cutaneous T-cell lymphoma (CTCL) patients treated with mogamulizumab with blood involvement, compared to vorinostat.